skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: LONG TERM EXPERIENCES WITH THE USE OF P$sup 32$ IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Journal Article · · Journal of Nuclear Medicine (U.S.)
OSTI ID:4748352

A series of 161 patients with chronic lymphocytic leukemia, (C.L.L.), 30 (18.6 per cent) of whom have survived from 10 to 31 years after onset, is presented. Twenty of these long-survival group patients are still living. Survival times were calculated from onset of symptomatology or diagnosis in asymptomatic cases; diagnosis; and first visit to Donner Laboratory. Analysis of symptomatology, physical findings, and laboratory data at the time of diagnosis for the 2 groups indicates that there is no absolute measure for prognosis. The important conclusion from this study re-emphasizes the fact that the diagnosis of C.L.L. can be compatible with many years of useful life and should bring reassurance to both doctor and patient that the disease follows a relatively benign course in an appreciable number of cases. Therapy was primarily with P/ sup 32/. No cases of acute leukemia were observed nor was the incidence of malignancies increased as a result of treatment. No other sequelae were encountered that would contraindicate the use of radiation. Pneumonia as a cause of death was significantly higher for the group dying before 1948, while for the same interval coronary disease or its sequelae was responsible for death in a percentage less than half that of the later period. While hemolytic complications may develop at any stage of C.L.L., they tended to occur more frequently in those patients in whom the course had been long and slowly progressive. Subjective and objective improvement occurred in those patients treated with oral androgens. Further work is indicated to associate a direct leukemic suppressive effect. Comparison of future studies would be facilitated if survival statistics are determined by some method similar to that used in this series. (auth)

Research Organization:
Univ. of California, Berkeley
NSA Number:
NSA-17-015697
OSTI ID:
4748352
Journal Information:
Journal of Nuclear Medicine (U.S.), Vol. Vol: 4; Other Information: Orig. Receipt Date: 31-DEC-63
Country of Publication:
Country unknown/Code not available
Language:
English